Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines
Daniel G. Haller, Jim Cassidy, Stephen John Clarke et al. · Journal of Clinical Oncology · 2008
PURPOSE: We conducted a retrospective analysis of safety data from randomized, single-agent fluoropyrimidine clinical trials (bolus fluorouracil/leucovorin [FU/LV] and capecitabine) to test the hypothesis that there are regional differences in fluoropyrimidine tolerability. METHODS: Treatment-related safety data from three phase III clinical studies were analyzed by multivariate analysis: two comparing capecitabine with bolus FU/LV in metastatic colorectal cancer (MCRC) and one comparing capecitabine plus oxaliplatin (XELOX) with bolus FU/LV as adjuvant treatment for colon cancer. The United States (US) was compared with non-US countries (all three studies) and with the rest of the world and East Asia (adjuvant study). RESULTS: In the MCRC studies (n = 1,189), more grade 3/4 adverse events (AEs; relative risk [RR], 1.77), dose reductions (RR, 1.72), and discontinuations (RR, 1.83) were reported in US versus non-US patients. Likewise, in the adjuvant colon cancer study (n = 1,864), more grade 3/4 AEs (RR, 1.47) and discontinuations (RR, 2.09) were reported in US versus non-US patients. After further dividing non-US patients into those in East Asia and the rest of the world, differential RRs for related grade 3/4 AEs, grade 4 AEs, and serious AEs were again observed, with East Asian patients having the lowest and US patients the highest RR. CONCLUSION: Regional differences exist in the tolerability profiles of fluoropyrimidines. More treatment-related toxicity was reported in the US compared with the rest of the world for bolus FU/LV and capecitabine in first-line MCRC and adjuvant colon cancer. In the adjuvant setting, a range of fluoropyrimidine tolerability was observed, with East Asian patients having the lowest, and US patients the highest, RR.
Cited by 252 works. doi:10.1200/jco.2007.15.2090
Authors
- Daniel G. Haller
- Jim Cassidy
- Stephen John Clarke
- David Cunningham
- Eric Van Cutsem
- Paulo M. Hoff
- Mace L. Rothenberg
- Leonard B. Saltz
- Hans‐Joachim Schmoll
- Carmen Joseph Allegra
- Joseph R. Bertino
- Jean-Yves Douillard
- Bengt G. Gustavsson
- Gerard Alain Milano
- Michael J. O’Connell
- Youcef M. Rustum
- Josep M. Tabernero
- Frank Gilberg
- Florin Sirzén
- Chris J. Twelves
References
- Cancer: Principles and Practice of Oncology.
- Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.
- A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study.
- Efficacy of adjuvant fluorouracil and folinic acid in colon cancer
- Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study
- Capecitabine as Adjuvant Treatment for Stage III Colon Cancer
- Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study
- First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorin
- Venous Thromboembolism Associated With Long-Term Use of Central Venous Catheters in Cancer Patients
- Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials